Abstracts tagged "cytokines"

Abstract Number: 1878 • ACR Convergence 2022
Identification of Serum Biomarkers Associated with Muscle Inflammation Detected on MRI in Polymyositis/dermatomyositis
Haruna Matsuo¹, Toshimasa Shimizu¹, Tomohiro Koga¹, Nozomi Oki², Masataka Uetani² and Atsushi Kawakami³, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Muscle inflammation is a major clinical manifestation in patients with polymyositis/dermatomyositis (PM/DM). Phenotypes of PM/DM patients, especially those with interstitial lung diseases, are known…
Abstract Number: 0722 • ACR Convergence 2021
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Alexandrine Mahoudeau¹, Céline Anquetil², Nozomu Tawara¹, Hossein Khademian¹, Damien Amelin¹, Yves Allenbach³ and Olivier Benveniste³, ¹Center of Research in Myology, Sorbonne University, Paris, France, ²Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France
Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
Abstract Number: 1531 • ACR Convergence 2021
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
Sarah Chang¹, Allan Feng¹, Wenzhao Meng², Sokratis Apostolidis², Elisabeth Mack³, Maja Artandi¹, Linda Barman¹, Kate Bennett⁴, Saborni Chakraborty¹, Iris Chang¹, Peggie Cheung¹, Sharon Chinthrajah¹, Shaurya Dhingra¹, Evan Do¹, Amanda Finck⁴, Andrew Gaano⁴, Reinhard Gessner⁵, Heather Giannini⁴, Joyce Gonzalez⁴, Sarah Greib³, Margrit Gündisch³, Alex Hsu¹, Alex Kuo¹, Monali Manohar¹, Rong Mao¹, Indira Neeli⁶, Andreas Neubauer³, Oluwatosin Oniyide², Abigail Powell¹, Rajan Puri¹, Harald Renz³, Jeffrey Schapiro⁷, Payton Weidenbacher¹, Rich Wittman¹, Neera Ahuja¹, Ho-Ryun Chung³, Pras Jagannathan¹, Judith James⁸, Peter Kim¹, Nuala Meyer², Kari Nadeau¹, Marko Radic⁶, William Robinson⁹, Upinder Singh¹, Taia Wang¹, John Wherry⁴, Chrysanthi Skevaki³, Eline Luning Prak⁴ and Paul Utz¹⁰, ¹Stanford, San Francisco, ²University of Pennsylvania, Philadelphia, PA, ³Marburg University, Marburg, Germany, ⁴UPenn, Philadelphia, PA, ⁵University of Marburg, Marburg, Germany, ⁶UTHSC, Memphis, TN, ⁷KPNC Regional Laboratory, Berkeley, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Stanford, CA
Background/Purpose: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features…
Abstract Number: 0867 • ACR Convergence 2021
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Christopher Oliveira¹, Yenealem Temesgen-Oyelakin², Mohammad Naqi³, Nidhi Patel², Philip Parel², Massimo Gadina⁴, Stefania Dell'Orso², Stephen Brooks², Sarthak Gupta⁵, Nehal Mehta⁶, Sarfaraz Hasni³ and Mariana Kaplan³, ¹National Institutes of Health (NIH), Vienna, VA, ²National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with enhanced cardiovascular (CV) risk linked to both traditional Framingham risk factors and lupus-specific immune dysregulation. Characterizing an…
Abstract Number: 1577 • ACR Convergence 2021
Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout
Adela Navratilova¹, Veronika Voclonová², Hana Hulejová², Lucie Andrés Cerezo¹, Markéta Pavlíková³, Viktor Bečvář², Jakub Zavada¹, Karel Pavelka⁴, Ladislav Senolt⁴ and Blanka Stiburkova⁵, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: IL-37 is an anti-inflammatory cytokine, member of IL-1 family, related to inflammatory and autoimmune diseases. Here we aimed to investigate the association of genetic…
Abstract Number: 1000 • ACR Convergence 2021
Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
Huaping Qin¹, Patricia Oliveira¹, Tiffany Yan¹, Robert Terkeltaub² and Ru Liu Bryan³, ¹University of California San Diego, La Jolla, CA, ²VA/UCSD, San Diego, CA, ³University of California San Diego and VASDHS, San Diego, CA
Background/Purpose: CD38 can function as a degrading enzyme of nicotinamide adenine dinucleotide (NAD), a critical metabolic intermediate serving as enzyme cofactor in redox reactions and…
Abstract Number: 1645 • ACR Convergence 2021
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
Joshua Baker¹, Bryant England², Michael George¹, Katherine Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Paul Monach⁶, Gary Kunkel⁷, Brian Sauer⁷, Bartlett Hamilton⁸, Carlos Hunter², Michael Duryee², Geoffrey Thiele² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁶Brigham and Women's Hospital, Boston, MA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Nebraska, Omaha, NE
Background/Purpose: Adipokines are metabolic regulators and are associated with adverse outcomes in chronic conditions and among older adults. Elevations in one adipokine, adiponectin, have been…
Abstract Number: 1003 • ACR Convergence 2021
Significant Enrichment of Pathogenic CD206+CD163+ Macrophages in Rheumatoid Arthritis Synovial Tissue with Distinct Transcriptional Signatures
Megan Hanlon¹, Mary Canavan², Nuno Neto³, Qingxuan Song⁴, Phil Gallagher⁵, Ronan Mullan⁶, Conor Hurson⁷, Barry Moran³, Michael Monaghan³, Sunil Nagpal⁸, Douglas Veale⁹ and Ursula Fearon³, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Santry, Ireland, ³Trinity College Dublin, Dublin, Ireland, ⁴Janssen Research & Development LLC, Spring House, PA, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶Tallaght University Hospital, Dublin, Ireland, ⁷St Vincents University Hospital, Dublin, Ireland, ⁸Janssen Research, Collegeville, PA, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Synovial tissue macrophages are an exquisitely plastic pool of innate cells that play a key role in RA disease progression. However, the precise nature,…
Abstract Number: 1768 • ACR Convergence 2021
Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity
Risa Wakiya¹, Kiyo Ueeda¹, Hiromi Shimada¹, Shusaku Nakashima¹, Mikiya Kato¹, Taichi Miyagi², Mansour mai¹, Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹, Tomohiro Kameda¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: In systemic lupus erythematosus (SLE), atherosclerosis is strongly associated with vital prognosis. On the other hand, arteriosclerosis is strongly influenced by serum adipokines. The…
Abstract Number: 0011 • ACR Convergence 2021
Differential Inflammation-mediated Function of Prokineticin 2 in the Synovial Fibroblasts of Patients with Rheumatoid Arthritis Compared to Osteoarthritis
Kentaro Noda, Bianca Dufner and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: Prokineticin 2 (PK2) is a secreted protein involved in several pathological and physiological processes, including the regulation of inflammation, sickness behaviors, and the circadian…
Abstract Number: 1006 • ACR Convergence 2021
MAA Modified and/or Citrullinated Proteins Stimulate Macrophages and Human Fibroblast-Like Synoviocytes to Increase the Secretion/Expression of Fractalkine Ligand (CX3CL1) and Fractalkine Receptor (CX3CR1)
Nozima Aripova, Michael Duryee, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In rheumatoid arthritis (RA) synovium, activated synovial fibroblasts and macrophages release inflammatory mediators that affect surrounding cells and accelerate disease progression. One such chemokine…
Abstract Number: 1771 • ACR Convergence 2021
First-in-Human Safety, Pharmacokinetic and Pharmacodynamic Study of Escalating Single- and Multiple-Doses of BMS-986256, a Novel, Potent, Oral Inhibitor of TLR7 and TLR8
Melanie Harrison¹, Manoj Chiney¹, Diane Shevell², Lixian Dong³, Michelle Dawes¹ and Ihab Girgis³, ¹Bristol Myers Squibb, Lawrenceville, NJ, ²Bristol Myers Squibb, Lawrenceville, ³Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Toll-like receptor (TLR)7 and TLR8 are endosomal receptors that are normally activated by pathogen-associated RNA. They are also activated by self-RNA as part of…
Abstract Number: 0032 • ACR Convergence 2021
IL-40: A New B-cell Associated Cytokine Up-regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates with Disease Activity, Autoantibodies and NETosis
Adela Navratilova¹, Lucie Andrés Cerezo¹, Hana Hulejová², Viktor Bečvář², Michal Tomcik³, Dana Tegzova², Martina Olejárová¹, David Veigl⁴, Karel Pavelka³, Jiri Vencovsky² and Ladislav Senolt³, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴First Orthopaedic Clinic, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Interleukin 40 (IL-40) is recently identified B cell - associated cytokine implicated in humoral immune responses and in B cell development and homeostasis. As…
Abstract Number: 1008 • ACR Convergence 2021
Synovial Fluid IL-36γ in Patients with Enthesitis Related Arthritis (ERA) Correlates with Disease Activity and Leads to Production of IL-6 by Fibroblast Like Synoviocytes
Amita Aggarwal, Sanjukta Majumder and Shivika Guleria, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: IL-36 has been implicated in the pathogenesis of spondyloarthropathies (SpA) like psoriasis and IBD. Enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA)…
Abstract Number: 1837 • ACR Convergence 2021
KL-6, CXCL11 and CTGF Are Potential Biomarkers in Response to Treatment in CTD-ILD
Yu-Hsiang Chiu¹, Mareye Voortman¹, Eveline Delemarre¹, Stefan Nierkens¹, Pim de Jong¹, Firdaus Mohamed Hoesein¹, Jan Grutters², Jacob van Laar¹ and Julia Spierings³, ¹University Medical Centre Utrecht, Utrecht, Netherlands, ²St. Antonius Hospital, Nieuwegein, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Connective tissue disease related interstitial lung disease (CTD-ILD) is common and an important cause of morbidity and mortality. We aimed to identify biomarkers in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].